首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTF1 |
| Uniprot No | Q16619 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-201aa |
| 氨基酸序列 | MSRREGSLED PQTDSSVSLL PHLEAKIRQT HSLAHLLTKY AEQLLQEYVQ LQGDPFGLPS FSPPRLPVAG LSAPAPSHAG LPVHERLRLD AAALAALPPL LDAVCRRQAE LNPRAPRLLR RLEDAARQAR ALGAAVEALL AALGAANRGP RAEPPAATAS AASATGVFPA KVLGLRVCGL YREWLSRTEG DLGQLLPGGS A |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTF1(Cardiotrophin-1)重组蛋白的模拟参考文献示例，供参考：
---
1. **文献名称**: "Cloning and expression of cardiotrophin-1. a cytokine involved in cardiac cell growth"
**作者**: Pennica D, et al.
**摘要**: 该研究首次报道了CTF1的基因克隆及重组蛋白表达，证明其通过激活gp130受体信号通路促进心肌细胞存活和肥大，为心脏发育研究提供了关键工具。
2. **文献名称**: "Cardiotrophin-1 activates a distinct form of cardiac hypertrophy"
**作者**: Hirota H, et al.
**摘要**: 通过重组CTF1蛋白实验，揭示了其诱导心肌肥大的独特机制，区别于其他促肥大因子，可能与心力衰竭病理过程相关。
3. **文献名称**: "Structural characterization of recombinant human cardiotrophin-1 and its functional implications"
**作者**: Robledo O, et al.
**摘要**: 解析了重组人CTF1蛋白的晶体结构，阐明其与受体结合的分子机制，为靶向药物设计奠定基础。
4. **文献名称**: "Cardiotrophin-1 in metabolic regulation: effects of recombinant CTF1 on adipose tissue"
**作者**: Moreno-Aliaga MJ, et al.
**摘要**: 研究发现重组CTF1蛋白可调节脂肪代谢，改善胰岛素敏感性，提示其在代谢性疾病中的潜在治疗价值。
---
**注**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如"cardiotrophin-1 recombinant protein")获取最新信息。经典研究多发表于1990-2000年代，近年研究可能聚焦于疾病机制或治疗应用。
CTF1 (Cardiotrophin-1) is a cytokine belonging to the interleukin-6 (IL-6) family, initially identified for its role in promoting cardiac myocyte survival and hypertrophy. It binds to a receptor complex comprising glycoprotein 130 (gp130) and leukemia inhibitory factor receptor (LIFR), activating downstream signaling pathways such as JAK-STAT, MAPK, and PI3K/Akt. This multifunctional protein is expressed in various tissues, including the heart, skeletal muscle, and nervous system, and is implicated in diverse physiological processes, including cell proliferation, differentiation, and anti-apoptotic responses.
Recombinant CTF1 is produced using genetic engineering techniques, typically through expression in bacterial (e.g., *E. coli*) or mammalian cell systems. The recombinant form retains the biological activity of native CTF1. enabling research into its therapeutic potential. Studies highlight its cardioprotective effects in models of heart failure, ischemia-reperfusion injury, and hypertrophy. Additionally, CTF1 demonstrates neurotrophic properties, supporting neuronal survival and regeneration, which has spurred interest in neurodegenerative disease research. Its role in metabolism and energy homeostasis, particularly in regulating skeletal muscle function and adipose tissue, further expands its biomedical relevance.
Despite promising applications, challenges remain in optimizing CTF1’s delivery and minimizing off-target effects due to its pleiotropic actions. Current research focuses on understanding tissue-specific signaling mechanisms and developing targeted therapies. Recombinant CTF1 also serves as a critical tool for elucidating molecular pathways in development, disease models, and regenerative medicine, making it a versatile candidate for both basic science and translational investigations.
×
